• Molecular NameTolazoline
  • SynonymNA
  • Weight160.22
  • Drugbank_IDDB00797
  • ACS_NO59-98-3
  • Show 3D model
  • LogP (experiment)2.65
  • LogP (predicted, AB/LogP v2.0)1.98
  • pka10.3
  • LogD (pH=7, predicted)-0.98
  • Solubility (experiment)0.373 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-0.75
  • LogSw (predicted, AB/LogsW2.0)6.09
  • Sw (mg/ml) (predicted, ACD/Labs)0.48
  • No.of HBond Donors1
  • No.of HBond Acceptors2
  • No.of Rotatable Bonds2
  • TPSA24.39
  • StatusFDA approved; US withdrawn
  • AdministrationIV
  • PharmacologyA non-selective competitive α-adrenergic receptor antagonist. It is a vasodilator that is used to treat spasms of peripheral blood vessels (as in acrocyanosis). It has also been used successfully as an antidote to reverse the severe peripheral vasoconstriction which can occur as a result of overdose with certain 5-HT2A agonist drugs such as LSD, DOB and Bromodragonfly and can lead to gangrene if untreated.
  • Absorption_value90.0
  • Absorption (description)N/A
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein binding23.0
  • Volume of distribution (VD)1.61 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmN/A
  • Half lifeN/A
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)N/A